Narcolepsy
Drug research and approvals for narcolepsy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 34 studies of narcolepsy are recruiting on ClinicalTrials.gov, Health Canada has authorized 22 drug trials for it since 2013, FDA has 13 approved and 7 open orphan designations naming it, and the EU has 3 authorised medicines for it.
- Recruiting worldwide: 34
- Trials authorized in Canada: 22
- FDA orphan approvals: 13
- EU medicines: 3
Recruiting Now
Newest start dates first, of 34 recruiting on ClinicalTrials.gov ↗- A Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE)NCT07540364 · Phase 3 · Suven Life Sciences Limited · starts Sep 1, 2026
- A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1…NCT07540897 · Phase 3 · Alkermes, Inc. · starts Aug 13, 2026
- Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1NCT07727239 · Not applicable · Xijing Hospital · starts Aug 1, 2026
- A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IHNCT07625280 · Phase 3 · Jazz Pharmaceuticals · starts Jul 9, 2026
- Decreasing Nightmares in Adults With NarcolepsyNCT06383806 · Not applicable · University of Utah · starts Jul 1, 2026
- A Study of TAK-360 in People With Narcolepsy or Idiopathic HypersomniaNCT07646678 · Phase 2 / Phase 3 · Takeda · starts Jun 11, 2026
- A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)NCT07633301 · Phase 2 · Takeda · starts Jun 4, 2026
- A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With NarcolepsyNCT07675135 · Phase 3 · Harmony Biosciences Management, Inc. · starts Jun 4, 2026
- A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central…NCT07598708 · Phase 2 / Phase 3 · Centessa Pharmaceuticals (UK) Limited · starts May 29, 2026
- A Phase 1, First-in-human Study of VX-433NCT07584434 · Phase 1 · Vertex Pharmaceuticals Incorporated · starts May 21, 2026
Trials Authorized in Canada
The 10 newest of 22; search them all in Canada trials| Sep 4, 2026 | A randomized, double-blind, 3-arm parallel design study to investigate the efficacy, safety, tolerability, and pharmacokinetics of cleminorexton compared with…CLEMINOREXTON (ORX750) | CENTESSA PHARMACEUTICALS (UK) LIMITED | Pending |
| Jul 28, 2026 | An open-label, long-term extension study to investigate the safety, tolerability, and durability of treatment effect of alks 2680 in participants with…ALIXOREXTON (ALKS 2680) | Alkermes | Pending |
| May 12, 2026 | A phase 3, randomized, double-blind, placebo-controlled, efficacy and safety study of hbs-301 in participants with narcolepsy followed by an open-label…PITOLISANT (HBS-301) | HARMONY BIOSCIENCES MANAGEMENT, INC. | Ongoing |
| May 7, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alks 2680 in adults with narcolepsy type 1ALIXOREXTON (ALKS 2680) | Alkermes | Ongoing |
| Mar 19, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alks 2680 in adults with narcolepsy type 2ALIXOREXTON (ALKS 2680) | Alkermes | Ongoing |
| Mar 12, 2026 | A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of alks 2680 in adults with narcolepsy type 1ALIXOREXTON (ALKS 2680) | Alkermes | Ongoing |
| Jan 16, 2026 | A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of e2086 in adults with narcolepsyLEDASOREXTON (E2086) | Eisai | Ongoing |
| Nov 28, 2025 | A long-term extension study of the safety and efficacy of cleminorexton in participants with narcolepsy and idiopathic hypersomnia who completed a sponsored…CLEMINOREXTON (ORX750) | CENTESSA PHARMACEUTICALS (UK) LIMITED | Ongoing |
| Feb 21, 2025 | A phase 2a, randomized, double-blind, placebo controlled study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of orx750 in subjects with…CLEMINOREXTON (ORX750) | CENTESSA PHARMACEUTICALS (UK) LIMITED | Ongoing |
| Aug 14, 2024 | A long-term extension study to evaluate the safety and tolerability of tak-861 in participants with selected central hypersomnia conditionsOVEPOREXTON (TAK-861) | Takeda Pharmaceuticals USA | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 20| Nov 12, 2026 | Orzeyfultreatment of narcolepsy type 1 (narcolepsy with cataplexy) in adult patients | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Feb 13, 2026 | Wakixtreatment of excessive daytime sleepiness (EDS) or cataplexy in patients 6 years of age and older with narcolepsy | Harmony Biosciences Management, Inc. | Approved |
| Oct 16, 2024 | Lumryztreatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy | Flamel Ireland Limited dba Avadel Ireland | Approved |
| Jun 21, 2024 | Wakixtreatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy and treatment of EDS in pediatric patients 6… | Harmony Biosciences Management, Inc. | Approved |
| May 1, 2023 | LumryzTreatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy | Flamel Ireland Limited dba Avadel Ireland | Approved |
| Oct 13, 2020 | WAKIX®treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy | Harmony Biosciences Management, Inc. | Approved |
| Jul 21, 2020 | XywavXYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with… | Jazz Pharmaceuticals Ireland Limited | Approved |
| Aug 14, 2019 | WAKIXWAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy | Harmony Biosciences Management, Inc. | Approved |
| Jun 17, 2019 | SunosiSUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy | Axsome Malta, Ltd. | Approved |
| Oct 26, 2018 | XyremXyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with… | Jazz Pharmaceuticals Ireland Limited | Approved |
| Nov 18, 2005 | XyremTreatment of excessive daytime sleepiness in patients with narcolepsy | Jazz Pharmaceuticals Ireland Limited | Approved |
| Jul 17, 2002 | XyremTreatment of cataplexy associated with narcolepsy | Jazz Pharmaceuticals Ireland Limited | Approved |
| Dec 24, 1998 | ProvigilImprove wakefulness in patients with excessive daytime sleepiness associated with narcolepsy. | Cephalon, Inc. | Approved |
| Jun 12, 2019 | 4-((L-valyl)oxy)butanoic acidTreatment of Narcolepsy | Avadel CNS Pharmaceuticals, LLC | Designated |
| Oct 15, 2018 | reboxetineTreatment of narcolepsy | Axsome Therapeutics, Inc. | Designated |
Medicines Authorised in the EU
Newest first| Jan 16, 2020 | Sunosisolriamfetol | Atnahs Pharma Netherlands B.V. | EMA ↗ |
| Mar 31, 2016 | Wakixpitolisant · orphan | Bioprojet Pharma | EMA ↗ |
| Oct 13, 2005 | Xyremsodium oxybate | UCB Pharma Ltd | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA